Protein Engineering: A New Frontier for Biological Therapeutics
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Protein engineering holds the potential to transform the metabolic drug landscape through the development of smart, stimulusresponsive drug systems. Protein therapeutics are a rapidly expanding segment of Food and Drug Administration approved drugs that will improve clinical outcomes over the long run. Engineering of protein therapeutics is still in its infancy, but recent general advances in protein engineering capabilities are being leveraged to yield improved control over both pharmacokinetics and pharmacodynamics. Stimulus- responsive protein therapeutics are drugs which have been designed to be metabolized under targeted conditions. Protein engineering is being utilized to develop tailored smart therapeutics with biochemical logic. This review focuses on applications of targeted drug neutralization, stimulus-responsive engineered protein prodrugs, and emerging multicomponent smart drug systems (e.g., antibody-drug conjugates, responsive engineered zymogens, prospective biochemical logic smart drug systems, drug buffers, and network medicine applications).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Network medicine: a network-based approach to human disease
Barabási, A.-L., Gulbahce, N., & Loscalzo, J. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2918 · Cited by 5,034
Structural Basis of the Drug-binding Specificity of Human Serum Albumin
Ghuman, J., Zunszain, P. A., Petitpas, I., Bhattacharya, A. A., Otagiri, M., & Curry, S. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.07.075 · Cited by 1,941
Chemistry and biology of reactive oxygen species in signaling or stress responses
Dickinson, B. C., & Chang, C. J. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.607 · Cited by 1,821
PAS Domains: Internal Sensors of Oxygen, Redox Potential, and Light
Taylor, B. L., & Zhulin, I. B. (1999) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.63.2.479-506.1999 · Cited by 1,632 · cited 1×
“In response to blue light, LOV domains undergo a reversible allosteric shift due to the formation of a covalent bond between a conserved cysteine residue in the core of the protein and a carbon atom of the flavin cofactor’s isoalloxazine ring [85, 86].”
BackgroundThe cryptochromes: blue light photoreceptors in plants and animals
Chaves, I., Pokorny, R., Byrdin, M., Hoang, N., Ritz, T., Brettel, K., Essen, L.-O., van der Horst, G. T. J., Batschauer, A., & Ahmad, M. (2011) · Annual Review of Plant Biology · doi:10.1146/annurev-arplant-042110-103759 · Cited by 845 · cited 1×
“In phytolases, electron transfer then proceeds from the excited FADH−* through three conserved tryptophan residues to a pyrimidine dimer, repairing the DNA by splitting it back into monomers [92].”
BackgroundTherapeutic Protein–Polymer Conjugates: Advancing Beyond PEGylation
Pelegri-O’Day, E. M., Lin, E.-W., & Maynard, H. D. (2014) · Journal of the American Chemical Society · doi:10.1021/ja504390x · Cited by 622 · cited 4×
“Additionally, protein engineering efforts to increase in vivo stability such as PEGylation [31], and methods to reduce immunogenicity and antigenicity [32], while of great clinical significance, are beyond the scope of this review.”
BackgroundInfluentialA robustness-based approach to systems-oriented drug design
Kitano, H. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2195 · Cited by 488 · cited 1×
“It uses new quantitative methods to measure signaling network status, computational methods to model the signaling network, and multistage, multicomponent drug treatment programs based on measured network status and model predictions [122].”
MethodExtending Serum Half-life of Albumin by Engineering Neonatal Fc Receptor (FcRn) Binding
Andersen, J. T., Dalhus, B., Viuff, D., Ravn, B. T., Gunnarsen, K. S., Plumridge, A., Bunting, K., Antunes, F., Williamson, R., Athwal, S., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.549832 · Cited by 167
Cited by
Recent advances in (therapeutic protein) drug development
Lagassé, H. A. D., Alexaki, A., Simhadri, V. L., Katagiri, N. H., Jankowski, W., Sauna, Z. E., & Kimchi-Sarfaty, C. (2017) · F1000Research · doi:10.12688/f1000research.9970.1 · Cited by 481
“BTDs, one third (10) of which were protein drugs.”
BackgroundProtein structure generation via folding diffusion
Wu, K. E., Yang, K. K., Berg, R. V. D., Zou, J. Y., Lu, A. X., & Amini, A. P. (2022) · arXiv · doi:10.48550/arxiv.2209.15611 · Cited by 193
Integrating Computational Design and Experimental Approaches for Next-Generation Biologics
Son, A., Park, J., Kim, W., Lee, W., Yoon, Y., Ji, J., & Kim, H. (2024) · Biomolecules · doi:10.3390/biom14091073 · Cited by 29
Recent advances in automated protein design and its future challenges
Setiawan, D., Brender, J., & Zhang, Y. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1465922 · Cited by 26
Metadata
- Authors
- Tobin, P., Richards, D., Callender, R., & Wilson, C.
- Venue
- Current Drug Metabolism
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2015-01-26
- Volume
- 15
- Issue
- 7
- Pages
- 743-756
- ISSN
- 1389-2002 (ISSN-L)
- OpenAlex
- W2103183317
- Cited by
- 54
- References
- 8
- FWCI
- 0.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Protein Engineering: A New Frontier for Biological Therapeutics. https://app.cochat.ai/papers/10.2174/1389200216666141208151524
- The paper
- Tobin, P., Richards, D., Callender, R., & Wilson, C. (2015). Protein Engineering: A New Frontier for Biological Therapeutics. Current Drug Metabolism. https://doi.org/10.2174/1389200216666141208151524
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.